Major 5'terminally deleted (5'TD) group-B enterovirus (EV-B) populations were identified in heart biopsies of patients with fulminant myocarditis or dilated cardiomyopathy suggesting that these 5'TD forms are key drivers of host-cell interaction in EV cardiac infections. To date, early emergence of EV-B 5'TD forms and its impact on type 1 IFN response during acute myocarditis remains unknown. Using quantitative RACE-PCR assay, we identified major EV-B 5'TD RNA populations in plasma or heart samples of acute myocarditis cases. Deletions identified within the 5' non-coding region of EV-B populations only affected secondary-structural elements of genomic RNA domain I and were distinguished in two major groups based on the extent of RNA structural deletions. Proportions of these two respective EV-B 5'TD population groups were positively or negatively correlated with IFN-β levels in plasma samples of myocarditis patients. Transfection of synthetic CVB3/28 RNAs harboring various 5'terminal full-length or deleted sequences into human cultured cardiomyocytes demonstrated that viral genomic RNA domain I possessed essential immunomodulatory secondary-structural elements responsible for IFN-β pathway induction. Overall, our results highlight the early emergence of major EVB-TD populations which deletions affecting secondary-structures of RNA domain I can modulate innate immune sensing mechanisms in cardiomyocytes of patients with acute myocarditis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371739 | PMC |
http://dx.doi.org/10.1038/s41598-020-67648-5 | DOI Listing |
Cardiooncology
January 2025
Division of Cardiology, Tel Aviv Sourasky medical Center, Tel Aviv, Israel.
Aims: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment outcomes. However, the response varies across different populations, and their use may lead to life-threatening cardiovascular (CV) events. While pre-treatment reduced left ventricular ejection fraction (LVEF) is considered a marker for high-risk cardiotoxicity and a contraindication for anthracycline and HER2-targeted therapies, there is limited evidence on the safety and efficacy of ICIs therapy in patients presenting with pre-treatment reduced LVEF.
View Article and Find Full Text PDFSaudi Med J
January 2025
From the College of Medicine (Bin Abdu, Assiri, Altasan, Alghamdi, Alshelawy, Alqahtani, Aljabr, Alnahdi, Alhamzani, Alghamdi, Alzahrani, Alshahrani, Alzahrani, Alshalawi), King Saud Bin Abdulaziz University for Health Sciences; from the Department of Medicine (Bin Abdu, Assiri, Altasan, Alghamdi, Alshelawy, Alqahtani, Aljabr, Alnahdi, Alhamzani, Alghamdi, Alzahrani, Alshahrani, Alzahrani, Alshalawi), King Abdullah International Medical Research Center; and from the Emergency Department (Alshalawi), King Abdulaziz Medical City Riyadh, Kingdom of Saudi Arabia.
Objectives: To assess the clinical course and long-term outcomes of complicated and uncomplicated AM in Saudi Arabia. Acute myocarditis (AM) can have different presentations and outcomes based on different factors, one of which is left ventricular ejection fraction (LVEF).
Methods: Data from 382 patients with suspected AM, admitted between January 2016 and October 2023, were reviewed.
Curr Cardiol Rep
January 2025
Robert M. Berne Cardiovascular Research Center, and Department of Medicine, DivisionofCardiovascularMedicine,HeartandVascularCenter, University of Virginia, Charlottesville, VA, USA.
Purposeof The Review: In this review article, we aim to provide an overview of the pathophysiology, the clinical features, the therapeutic management and prognosis of patients affected by Multisystemic inflammatory syndrome (MIS) with cardiac involvement, focusing on myocarditis and pericarditis.
Recent Findings: MIS is a multiorgan hyperinflammatory condition due to a cytokine storm following (within 4-12 weeks) SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection. First described in children, it also affects young adults without comorbidities, predominantly males with highly heterogeneous clinical manifestations, including cardiac involvement.
Clin Nucl Med
November 2024
Cardiology Department, CHU Orleans, Orleans, France.
Late-stage eosinophilic myocarditis (or Löffler endocarditis) is known to occur in patients with hypereosinophilic syndrome and can cause restrictive cardiomyopathy. Eosinophilic myocarditis is an acute life-threatening inflammatory disease of the heart that can be associated with cancer. We report a case of a 70-year-old White woman, previously treated for diffuse large B-cell lymphoma in remission, admitted for acute dyspnea with a 1-year history of hypereosinophilia.
View Article and Find Full Text PDFClin Nucl Med
February 2025
Cardiology Department, CHU Orleans, Orleans, France.
Late-stage eosinophilic myocarditis (or Löffler endocarditis) is known to occur in patients with hypereosinophilic syndrome and can cause restrictive cardiomyopathy. Eosinophilic myocarditis is an acute life-threatening inflammatory disease of the heart that can be associated with cancer. We report a case of a 70-year-old White woman, previously treated for diffuse large B-cell lymphoma in remission, admitted for acute dyspnea with a 1-year history of hypereosinophilia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!